HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

In this episode of HOPA Now, Dr. Bernard Marini highlights the main clinical pearls of adult acute leukemias and myelodysplastic syndrome, including unique factors that affect dosing, drug monitoring factors, and guidelines, and the oncologic stewardship and dosing caps for various drug usage.

In this episode you will learn:

Adult Acute Leukemias & Myelodysplastic Syndrome: Top 10 Clinical Pearls

There are unique lenalidomide sensitivities for patients with deletion 5q.
Thrombopoietin mimetics and growth factors for patients with MDS
Guidelines for use of potent ASAL antifungals
Denosumab azomycin and oncologic stewardship and dosing caps
Secondary AML and oncologic stewardship outcomes and alternatives
Characteristics and management of IDH inhibitors and differentiation syndrome
Asparaginase and therapeutic drug monitoring and a comparison of adult versus pediatric patients reactions and survival rates
Blinatumomab and inotuzumab use and outcomes in patients with less disease burden
Balancing safety and efficacy of TKIs in patients with ph positive ALL

Mentioned in This Episode:

HOPA

Quotes:

“Patients with deletion 5q are uniquely sensitive to lenalidomide.” — Dr. Bernard Marini

“Given the flaws in the alpha trial and the meta-analysis, this is potentially a place for oncologic stewardship in avoidance in risk in a drug with no overall survival benefit.” — Dr. Bernard Marini

“IDH inhibitors in AML are fascinating agents.” — Dr. Bernard Marini

“Adults and young adult patients have significantly worse survival rates compared to pediatric ALL counterparts.” — Dr. Bernard Marini